Tags

Type your tag names separated by a space and hit enter

Consecutive case series of 244 age-related macular degeneration patients undergoing implantation with an extended macular vision IOL.
Eur J Ophthalmol. 2018 Mar; 28(2):198-203.EJ

Abstract

PURPOSE

To determine safety and visual outcomes in eyes with age-related macular degeneration (AMD) implanted with a novel intraocular lens (IOL) that delivers an optimized retinal image to all macular areas within 10 degrees of retinal eccentricity.

METHODS

This was a consecutive case series of 244 eyes with dry/stable wet AMD and logMAR visual acuity ≥0.3 implanted with iolAMD Eyemax monoTM (London Eye Hospital Pharma), a single-piece, injectable, hydrophobic acrylic IOL sited in the capsular bag. Primary outcome was safety. Secondary outcomes were changes in corrected distance visual acuity (CDVA) and corrected near visual acuity (CNVA) (logMAR).

RESULTS

Mean age at surgery was 80 years. Mean duration of follow-up was 3 months (range 1-16 months). No eyes had worsening of CDVA. Frequency of perioperative complications was equivalent to standard IOL implantation. Postoperative refractive outcomes were within ±1 D of the target refraction in 88% of cases. Mean preoperative CDVA improved from 1.06 to 0.71 postoperatively (mean of differences -0.35; 95% confidence interval [CI] -0.3886 to -0.3223; p<0.0001), equating to an approximate Early Treatment Diabetic Retinopathy Study gain of 18 letters. Mean preoperative CNVA (N-point; logMAR conversion) improved from 1.36 to 0.88 postoperatively (mean of differences -0.48; 95% CI -0.53 to -0.44; p<0.0001).

CONCLUSIONS

This novel IOL appears safe in the short to medium term. Improvements in postoperative CDVA and CNVA exceed those observed with standard implants.

Authors+Show Affiliations

1 London Eye Hospital, London - UK.1 London Eye Hospital, London - UK.2 Department of Ophthalmology, University of Heidelberg, Heidelberg - Germany.2 Department of Ophthalmology, University of Heidelberg, Heidelberg - Germany.2 Department of Ophthalmology, University of Heidelberg, Heidelberg - Germany.3 Optics Laboratory, University of Murcia, Murcia - Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28983894

Citation

Qureshi, Muhammad A., et al. "Consecutive Case Series of 244 Age-related Macular Degeneration Patients Undergoing Implantation With an Extended Macular Vision IOL." European Journal of Ophthalmology, vol. 28, no. 2, 2018, pp. 198-203.
Qureshi MA, Robbie SJ, Hengerer FH, et al. Consecutive case series of 244 age-related macular degeneration patients undergoing implantation with an extended macular vision IOL. Eur J Ophthalmol. 2018;28(2):198-203.
Qureshi, M. A., Robbie, S. J., Hengerer, F. H., Auffarth, G. U., Conrad-Hengerer, I., & Artal, P. (2018). Consecutive case series of 244 age-related macular degeneration patients undergoing implantation with an extended macular vision IOL. European Journal of Ophthalmology, 28(2), 198-203. https://doi.org/10.5301/ejo.5001052
Qureshi MA, et al. Consecutive Case Series of 244 Age-related Macular Degeneration Patients Undergoing Implantation With an Extended Macular Vision IOL. Eur J Ophthalmol. 2018;28(2):198-203. PubMed PMID: 28983894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Consecutive case series of 244 age-related macular degeneration patients undergoing implantation with an extended macular vision IOL. AU - Qureshi,Muhammad A, AU - Robbie,Scott J, AU - Hengerer,Fritz H, AU - Auffarth,Gerd U, AU - Conrad-Hengerer,Ina, AU - Artal,Pablo, Y1 - 2017/05/10/ PY - 2017/10/7/pubmed PY - 2018/5/15/medline PY - 2017/10/7/entrez KW - Age-related macular degeneration KW - Cataract KW - Eccentric fixation KW - Intraocular lens KW - Macular degeneration KW - Preferred retinal locus SP - 198 EP - 203 JF - European journal of ophthalmology JO - Eur J Ophthalmol VL - 28 IS - 2 N2 - PURPOSE: To determine safety and visual outcomes in eyes with age-related macular degeneration (AMD) implanted with a novel intraocular lens (IOL) that delivers an optimized retinal image to all macular areas within 10 degrees of retinal eccentricity. METHODS: This was a consecutive case series of 244 eyes with dry/stable wet AMD and logMAR visual acuity ≥0.3 implanted with iolAMD Eyemax monoTM (London Eye Hospital Pharma), a single-piece, injectable, hydrophobic acrylic IOL sited in the capsular bag. Primary outcome was safety. Secondary outcomes were changes in corrected distance visual acuity (CDVA) and corrected near visual acuity (CNVA) (logMAR). RESULTS: Mean age at surgery was 80 years. Mean duration of follow-up was 3 months (range 1-16 months). No eyes had worsening of CDVA. Frequency of perioperative complications was equivalent to standard IOL implantation. Postoperative refractive outcomes were within ±1 D of the target refraction in 88% of cases. Mean preoperative CDVA improved from 1.06 to 0.71 postoperatively (mean of differences -0.35; 95% confidence interval [CI] -0.3886 to -0.3223; p<0.0001), equating to an approximate Early Treatment Diabetic Retinopathy Study gain of 18 letters. Mean preoperative CNVA (N-point; logMAR conversion) improved from 1.36 to 0.88 postoperatively (mean of differences -0.48; 95% CI -0.53 to -0.44; p<0.0001). CONCLUSIONS: This novel IOL appears safe in the short to medium term. Improvements in postoperative CDVA and CNVA exceed those observed with standard implants. SN - 1724-6016 UR - https://www.unboundmedicine.com/medline/citation/28983894/Consecutive_case_series_of_244_age_related_macular_degeneration_patients_undergoing_implantation_with_an_extended_macular_vision_IOL_ L2 - https://journals.sagepub.com/doi/10.5301/ejo.5001052?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -